Novartis Aktie - NVS

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

114,29

Gebot

Fragen

Volumen

2.543.503

113,00 Tagesbereich 114,705

96,062 52-Wochen-Bereich 120,92

Marktkapitalisierung

225,733B

Handelsende

112,63

Handelsbeginn

113,385

Letzte Trade

114.29

Letzter Handelszeitpunkt

Finanzvolumen

US$ 289.998.512

VWAP

114,0154

Durchschnittliches Volumen (3 Mio.)

2.448.282

Ausgegebene Aktien

1.975.089.248

Dividendenrendite

Kurs-Gewinn-Verhältnis

18,95

Gewinn pro Aktie (EPS)

6,05

Erlöse

51,72B

Nettogewinn

11,94B

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, ca... Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.novartis.com

Hauptsitz

Basel, Che

Gegründet

Novartis AG is listed in the Pharmaceutical Preparations sector of the New York Börse with ticker NVS. The last closing price for Novartis was US$112,63. Over the last year, Novartis shares have traded in a share price range of US$ 96,062 to US$ 120,92.

Novartis currently has 1.975.089.248 shares in issue. The market capitalisation of Novartis is US$222,45 billion. Novartis has a price to earnings ratio (PE ratio) of 18.95.

Gesamtfluss

Bullisch

Nettoprämie

719k

Calls / Puts

100.00%

Käuf. / Verkä.

300.00%

OTM / ITM

25.00%

Sweeps

0.00%

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) PR...

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	3.27	2.9454152405	111.02	114.29	109.51	2137435	111.47353128	DR
4	1.81	1.60917496444	112.48	114.44	97.715	2564249	108.04206004	DR
12	8.73	8.27017809776	105.56	116.91	97.715	2448282	109.4507196	DR
26	2.48	2.21804847509	111.81	116.91	96.062	1922001	106.67699846	DR
52	16.44	16.8012263669	97.85	120.92	96.062	1548114	107.7175902	DR
156	25.05	28.0703720305	89.24	120.92	74.09	1783341	96.06492685	DR
260	26.95	30.8564231738	87.34	120.92	74.09	1892214	92.23954226	DR

NVS - Frequently Asked Questions (FAQ)

What is the current Novartis share price?

The current share price of Novartis is US$ 114,29

How many Novartis shares are in issue?

Novartis has 1.975.089.248 shares in issue

What is the market cap of Novartis?

The market capitalisation of Novartis is USD 222,45B

What is the 1 year trading range for Novartis share price?

Novartis has traded in the range of US$ 96,062 to US$ 120,92 during the past year

What is the PE ratio of Novartis?

The price to earnings ratio of Novartis is 18,95

What is the cash to sales ratio of Novartis?

The cash to sales ratio of Novartis is 4,38

What is the reporting currency for Novartis?

Novartis reports financial results in USD

What is the latest annual turnover for Novartis?

The latest annual turnover of Novartis is USD 51,72B

What is the latest annual profit for Novartis?

The latest annual profit of Novartis is USD 11,94B

What is the registered address of Novartis?

The registered address for Novartis is PO BOX, BASEL, 4002

What is the Novartis website address?

The website address for Novartis is www.novartis.com

Which industry sector does Novartis operate in?

Novartis operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
LEGLeggett and Platt Inc	US$ 9,5725 (31,67%)	10,81M
CCMConcord Medical Services Holdings Ltd	US$ 7,85 (30,62%)	267,83k
HIMSHims and Hers Health Inc	US$ 35,0501 (23,07%)	152,16M
VPGVishay Precision Group Inc	US$ 26,13 (18,18%)	908,82k
CLVTClarivate PLC	US$ 4,205 (17,13%)	13,6M
WOLFWolfspeed Inc	US$ 3,47 (-15,98%)	66,67M
PDMPiedmont Office Realty Trust Inc	US$ 5,75 (-15,44%)	7,8M
EATBrinker International Inc	US$ 136,82 (-14,84%)	7,94M
NSPInsperity Inc	US$ 67,21 (-14,51%)	1,92M
KFRCKforce Inc	US$ 36,59 (-14,43%)	682,89k
HIMSHims and Hers Health Inc	US$ 35,0501 (23,07%)	152,16M
FFord Motor Company	US$ 10,16 (1,40%)	141,98M
AMCRAmcor plc	US$ 9,34 (-3,01%)	141,88M
SNAPSnap Inc	US$ 9,09 (2,94%)	105,58M
PFEPfizer Inc	US$ 23,79 (3,21%)	98,52M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novartis AG (NVS) Börsenkurse

Novartis AG (NVS)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Novartis AG

Option-Flow Novartis (NVS)

Gesamtfluss

Bullisch

Nettoprämie

719k

Calls / Puts

100.00%

Käuf. / Verkä.

300.00%

OTM / ITM

25.00%

Sweeps

0.00%

NVS Neueste Nachrichten

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Tesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-Market

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HSBC Reports $8.5 Billion Profit; Boot Barn Announces New CEO and Projections; TMDX Drops 24%, VFC Surges 22%

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

NVS - Frequently Asked Questions (FAQ)

Beweger

NVS Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen